Evidence-based guide to using Mounjaro (tirzepatide) in special populations including transplant recipients, people living with HIV, older adults, and patients with renal or hepatic impairment.
TRICARE covers Mounjaro (tirzepatide) for type 2 diabetes with prior authorization. Learn formulary tier placement, step therapy requirements, appeal steps for denials, and out-of-pocket cost options for military beneficiaries.
A clinical review of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) safety data in adults aged 30 to 49, covering dosing, side effects, drug interactions, and monitoring.
Find out whether Cigna commercial plans cover NMN or nicotinamide riboside, including prior authorization criteria, formulary tier placement, appeal steps, and cash-pay alternatives.
A clinical comparison of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) costs against other NAD+ precursors, niacin, and IV NAD+ infusions, with an evidence-boundary review and dosing context.
A clinical review of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) safety in geriatric adults, covering renal considerations, drug interactions, dosing, and what trials have (and haven't) proven in the 65+ population.
A clinical timeline of NMN and NR from the 1906 discovery of NAD+ through modern human trials, FDA regulatory shifts, and ongoing longevity research.
A physician-level explanation of how nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) raise NAD+ levels, activate sirtuins and PARPs, and influence metabolic health.
State Medicaid programs do not cover NMN or nicotinamide riboside. Learn why these NAD precursors fall outside formulary coverage, what alternatives exist, and how to access them affordably.
Evidence-based monitoring schedule for nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) supplementation, including recommended labs, exam intervals, and safety biomarkers reviewed by physicians.
A clinical review of NMN and NR off-label applications, from insulin sensitivity to cardiovascular aging, graded by human trial evidence and mechanistic plausibility.
NMN supplements sit in a legal gray zone: the FDA excluded NMN from the dietary supplement definition in 2022, and the EU and UK have not authorized it.
NMN at 40°C is not stable long-term: unprotected powder loses 15-30% potency over 6 months at 40°C/75% RH, the ICH accelerated stability test standard.
BPC-157 pentadecapeptide is used off-label for GI healing. This evidence-based guide covers dosing protocols, preclinical data, safety signals, and what physicians should know before prescribing.
BPC-157 pentadecapeptide is used off-label for inflammation despite lacking FDA approval. Review the preclinical evidence, proposed mechanisms, monitoring requirements, and safety considerations.
A clinical evidence summary of BPC-157 pentadecapeptide for tendon repair, including preclinical trial data, proposed mechanisms, dosing protocols used in research, and what physicians should know about this off-label peptide.
A clinical review of CJC-1295 (modified GRF 1-29) for fat loss, including the limited trial data, mechanism of action through GH-axis stimulation, dosing protocols used in research, and why this peptide remains off-label with no FDA approval for any indication.
CJC-1295 modified GRF is used off-label for longevity. This guide covers dosing protocols, evidence quality, GH-axis physiology, safety data, and what the clinical research actually shows.
CJC-1295 (modified GRF 1-29) is used off-label for longevity and anti-aging. This evidence review covers the clinical data, monitoring requirements, safety signals, and what patients should discuss with their provider.
A clinical review of CJC-1295 (modified GRF 1-29) for recovery, including off-label evidence, GH-axis pharmacology, dosing protocols, and safety data.
Enclomiphene citrate is sometimes used off-label for gynecomastia. Learn about the evidence, dosing protocols, and how it compares to other SERMs like tamoxifen and raloxifene.
A clinical evidence summary of enclomiphene citrate used off-label for gynecomastia, including mechanism of action, trial data, dosing protocols, and how it compares to clomiphene and tamoxifen.
Evidence-based guide to off-label enclomiphene citrate use in secondary hypogonadism, including dosing protocols, clinical trial data, and comparison to clomiphene and TRT.
Enclomiphene citrate is used off-label for secondary hypogonadism to raise testosterone while preserving fertility. What the evidence actually shows, what remains unverified, and how monitoring should be structured.
Evidence review of off-label oral estradiol for cognitive decline prevention, including dosing protocols, the critical window hypothesis, key trial data from WHIMS and KEEPS, and clinical considerations.
A clinical evidence summary of oral estradiol for osteoporosis, including FDA-approved prevention indications, off-label treatment use, WHI trial data, dosing, and risk-benefit analysis.
Oral estradiol is used off-label for osteoporosis prevention and treatment in postmenopausal women. Review the evidence from WHI and other trials, bone density outcomes, fracture risk reduction, and the risk-benefit tradeoffs compared to FDA-approved alternatives.
Evidence-based guide to oral estradiol dosing for feminizing hormone therapy in transgender women, including off-label status, recommended protocols, monitoring, and risk management.
A comprehensive evidence summary on using oral estradiol for feminizing hormone therapy in transgender women, including dosing, efficacy, safety data, and guideline recommendations.
Oral estradiol is widely prescribed off-label for feminizing hormone therapy in transgender women. Learn about monitoring protocols, target lab values, VTE risk, and evidence-based dosing.
Compare estradiol patch labels and bone-density trial results, with clear distinctions between osteoporosis prevention, dose choice and fracture evidence.
How transdermal estradiol prevents postmenopausal bone loss, what monitoring you need on therapy, and the evidence behind dosing for skeletal protection.
Transdermal estradiol is used off-label for perimenopausal mood symptoms. Review the clinical trial data, recommended doses, monitoring protocols, and safety considerations.
Can an estradiol transdermal patch treat perimenopausal mood symptoms? We review the off-label evidence, FDA-approved indications, clinical trial data, risks, and how to talk to your provider.
Evidence-based guide to using estradiol transdermal patches for feminizing hormone therapy in transgender women, including dosing protocols, monitoring, and clinical outcomes.
A clinical evidence summary on using transdermal estradiol patches for feminizing hormone therapy in transgender women, covering dosing, safety, efficacy data, and guideline recommendations.
Off-label finasteride helped hair density in postmenopausal women at doses above 1 mg; the 1 mg male dose showed no benefit. Contraindicated in pregnancy.
Finasteride isn't FDA-approved for women, but doctors prescribe 1-5mg off-label for female pattern hair loss with strict pregnancy testing and lab monitoring.
Off-label finasteride (2.5-5mg) may help postmenopausal women with FPHL; contraindicated in pregnancy due to fetal risk. Results take 12-18 months.
Finasteride is used off-label for hirsutism in women. Review the clinical trial data, side-effect profile, pregnancy contraindication, dosing, and how it compares to spironolactone.
An evidence-based review of copper tripeptide GHK-Cu for cognitive function. Covers preclinical gene-expression data, animal findings, safety, and why no human trials exist for this off-label use.
Copper tripeptide GHK-Cu is being explored off-label for cognitive support. Learn what the preclinical evidence shows, how clinicians monitor patients, and what labs to track.
Copper tripeptide GHK-Cu is used off-label for hair growth. Review the preclinical evidence, limited human data, safety risks, and how it compares to FDA-approved options like minoxidil and finasteride.
A clinical review of copper tripeptide GHK-Cu for skin regeneration, including off-label status, trial evidence, safety profile, and how it compares to FDA-approved alternatives.
HeFH on max statins is FDA-approved for Leqvio (47.9% LDL-C drop, ORION-9); HoFH use is off-label, with ORION-5 showing about 19.8% reduction.
A clinical evidence summary of ipamorelin acetate for fat loss, including trial data, mechanism of action, dosing protocols, safety profile, and off-label status.
Ipamorelin acetate is used off-label for longevity and anti-aging. This evidence-based guide covers dosing protocols, growth hormone physiology, safety data, and what the clinical research actually shows.
Ipamorelin acetate is used off-label for longevity and anti-aging. Learn what the evidence actually shows, how clinicians monitor patients, and what blood work is required.
A clinical review of ipamorelin acetate used off-label for recovery, including evidence quality, dosing protocols, required lab monitoring, and safety considerations.
A clinical evidence summary of metformin's off-label use for cancer prevention, including key trials, biological mechanisms, and current guideline positions.
Metformin is FDA-approved for type 2 diabetes, but observational data suggest it may reduce cancer incidence. Here is what the trials show, what remains unproven, and how to monitor patients using metformin off-label for cancer risk reduction.
Metformin is prescribed off-label for longevity based on observational data and preclinical evidence. Here is what the clinical trials show, how physicians dose it, and what TAME will tell us.
TAME trial is still ongoing, no FDA approval yet. See required labs for off-label metformin use: eGFR, B12, lactate, liver panel and glucose intervals.
A clinical review of metformin's off-label use for longevity, including trial data, AMPK mechanisms, side effects, and who may or may not benefit from anti-aging metformin therapy.
Metformin is sometimes used off-label for nonalcoholic fatty liver disease (NAFLD). Learn what the evidence shows, how monitoring works, and what guidelines recommend.
Metformin is widely prescribed off-label for NAFLD, but clinical trials show limited histological benefit. Learn the real evidence, risks, tradeoffs, and better-studied alternatives.
Metformin isn't FDA-approved for PCOS but is used off-label to improve insulin sensitivity and ovulation. Learn required monitoring and dosing basics.
Metformin is used off-label for weight maintenance after initial weight loss. Review the clinical trial evidence, required lab monitoring, dosing protocols, and safety considerations for long-term use.
A clinical evidence summary of tirzepatide (Mounjaro) for heart failure, including SURMOUNT-HFpEF trial data, mechanism of action, current FDA-approved indications, and what the research means for patients with HFpEF.
Can Mounjaro (tirzepatide) be used for heart failure? Review the clinical trial data, off-label status, monitoring requirements, and what cardiologists recommend for HFpEF patients.